Tag Archives: regular
EMA, risks stem not regular therapy
Risks to the health of the patients (ANSA) – ROMA, 22 APR – may arise from the use non-regulated stem cell-based therapies. It means that it is the European Agency of medicines EMA. “Allows the producers to avoid compliance with … Continue reading